Nuvalent, Inc.

A first look beyond NSCLC ✨ We are proud to present preliminary clinical data for neladalkib, an investigational ALK-selective inhibitor, in patients with advanced #ALK- positive solid tumors outside of NSCLC at the ESMO - European Society for Medical Oncology Congress. #ESMO25 Learn More: https://lnkd.in/eF9BwKhC

At Nuvalent, every day is an opportunity to make an impact on the patients we aim to serve, alongside teammates who share the same goal. Careers with purpose, that’s #SomethingNu. Your next role starts here: https://lnkd.in/g6qZeV9S

📊 Join us at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics where we'll present new preclinical data further characterizing the intracranial activity of our investigational HER2-selective inhibitor, NVL-330. Learn more: https://lnkd.in/ejW-UEmX #biotech #Nuvalent

We know that navigating a diagnosis of advanced ROS1+ or ALK+ NSCLC for yourself or a loved one can feel overwhelming. That’s why we’ve launched Elevate Lung Cancer Care, a dedicated online initiative for the ROS1+ and ALK+ NSCLC communities. This website includes resources designed to help you: • Learn helpful information about advanced ROS1+ or ALK + NSCLC; • Plan your next steps through informed conversations with your care team; and • Connect with others in the lung cancer community and find support.   We hope that this empowers you to feel more informed, supported, and prepared for the road ahead.   Visit elevatelungcancercare.com to learn more.   #LungCancerAwareness #NSCLC #ALKPositive #ROS1Positive #PatientEducation #CancerCare #TheROS1ders

Nuvalent is proud to sponsor the GO2 for Lung Cancer 2025 Navigator Workshop & Centers of Excellence Summit this week.🌟 Learn more about GO2 for Lung Cancer: https://go2.org/ #biotech #lungcancer #oncology

Do you dream of making a difference? At Nuvalent, we combine precision-driven innovation with a team united by purpose. We’re looking for bold leaders ready to help us in our mission to maximize Patient Impact. Don’t just dream it, explore #SomethingNu: https://lnkd.in/g6qZeV9S

New faces, same #NuCrew spirit! Welcome Uyen, Sarah, Chris, and Erin! We’re thrilled to have you on board! 🎊

Culture is intentional. That’s why we set out with the intention to build #SomethingNu. From the beginning of Nuvalent, we envisioned a culture that Empowers every voice, drives innovation through Collaboration, and unites us through our shared commitment to maximizing Patient Impact. As the organization has scaled and our programs have advanced, these same principles continue to guide how the #NuCrew grows and works together. We are proud of what we’ve built, because we know how we work is as important as the work itself, and behind every scientific breakthrough are the people who make it possible. Explore how you can be a part of #SomethingNu: https://lnkd.in/g6qZeV9S

At Nuvalent, we believe that innovation starts with collaboration. Today on #WorldCancerResearchDay, we’re proud to recognize the patients, researchers, clinicians, and innovators across the globe who make progress in #cancer care possible. Together, we remind the world that #CancerResearchNeedsUsAll. Explore how you can get involved:worldcancerresearchday.com

Join Nuvalent CEO James Porter and CFO Alex Balcom, MBA, CPA next week at the UBS 2025 Virtual Oncology Day. Recordings of the webcast will be available on our website for 30 days. https://lnkd.in/ebp2ADXV $NUVL #biotech #oncology